A Multicenter Randomized Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin in Node Positive Postmenopausal Breast Cancer Patients.

Trial Profile

A Multicenter Randomized Trial of Sequential Epirubicin and Docetaxel Versus Epirubicin in Node Positive Postmenopausal Breast Cancer Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2016

At a glance

  • Drugs Docetaxel (Primary) ; Epirubicin (Primary) ; Tamoxifen
  • Indications Breast cancer; Early breast cancer
  • Focus Therapeutic Use
  • Acronyms DEVA
  • Most Recent Events

    • 08 Dec 2015 Accrual to date is 17%, according to United Kingdom Clinical Research Network record record.
    • 02 Dec 2011 Actual end date (31 Dec 2005) added as reported by ISRCTN: Current Controlled Trials.
    • 02 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top